Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 2/20 | 0.65 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.65 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | GPR132 | Q9UNW8 | 9/20 | 0.50 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.50 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1071229 | 0.83 | CA1 (0.60) | ECE1GPR132CMKLR2CMKLR1CA1 | |
| SCHEMBL6307446 | 0.81 | GPR132 (0.54) | ECE1GPR132CMKLR2CMKLR1CYP1A2 | |
| SCHEMBL1067785 | 0.80 | GPR132 (0.48) | ECE1GPR132CMKLR2CMKLR1CYP1A2 | |
| SCHEMBL6307451 | 0.78 | GPR132 (0.54) | ECE1GPR132CMKLR2CMKLR1CYP1A2 | |
| SCHEMBL12978378 | 0.76 | CA2 (0.61) | CYP1A2CYP3A4CYP2C9CA1CA2 | |
| SCHEMBL22473033 | 0.76 | CA2 (0.61) | CYP1A2CYP3A4CYP2C9CA1CA2 | |
| SCHEMBL2339741 | 0.76 | CA1 (0.58) | CA1CA2MMEACEKDM6B | |
| SCHEMBL2339748 | 0.76 | CA1 (0.58) | CA1CA2MMEACEKDM6B | |
| SCHEMBL4179516 | 0.75 | MME (0.58) | CYP1A2CYP3A4CYP2C9CA1CA2 | |
| SCHEMBL31355569 | 0.75 | CA2 (0.57) | CA1CA2MMEACEKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4035507-A | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | claimed |
| US-11969401-B2 | Compositions and methods for treating or limiting development of age-related macular degeneration | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-04-30 | — | — | US | disclosed |
| US-20220023245-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | disclosed |
| EP-3917504-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | Arizona Board of Regents on behalf of the University of Arizona (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160256-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-08-06 | — | — | WO | disclosed |
| US-9861600-B2 | Methods and compositions for treating and identifying compounds to treat age-related macular degeneration treatment | Arizona Board of Regents, A Body Corporate Of The State Of Arizona Acting For An On Behalf Of The University of Arizona (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160015665-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration Treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-21 | — | — | US | disclosed |
| US-9173862-B2 | Methods and compositions for treating and identifying compounds to treat age-related macular degeneration | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2015-11-03 | — | — | US | disclosed |
| US-20110044908-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration | Arizona Board of Regents, a body Corporate of the State of Arizona, acting for and on behalf of the (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2273988-A2 | METHODS AND COMPOSITIONS FOR TREATING AND IDENTIFYING COMPOUNDS TO TREAT AGE-RELATED MACULAR DEGENERATION | Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009129497-A2 | METHODS AND COMPOSITIONS FOR TREATING AND IDENTIFYING COMPOUNDS TO TREAT AGE-RELATED MACULAR DEGENERATION | ARIZONA BOARD OF REGENTS, A BODY CORP. OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2009-10-22 | — | — | WO | disclosed |
| US-4065566-A | PRO-DRUG FORM OF L-DOPA, PARKINSON*S DISEASE | INTERX RESEARCH CORPORATION (US) | 1977-12-27 | — | — | US | disclosed |
| US-4035507-A | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease | INTERX RESEARCH CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
| US-3998799-A | FOR TREATMENT OF PARKINSON'S DISEASE | INTERX RESEARCH CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023245-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | MTNR1A, MC1R, MTNR1B | ERCC1 4246/4885ERCC4 3840/4885ECE1 2888/4885 |
| US-11969401-B2 | Compositions and methods for treating or limiting development of age-related macular degeneration | MTNR1A, MC1R, MTNR1B | ERCC1 4246/4885ERCC4 3840/4885ECE1 2888/4885 |
| US-20110044908-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration | PDE6C, AGER, PDE6D | ERCC1 1778/4885ERCC4 674/4885ECE1 1135/4885 |
| US-20160015665-A1 | Methods and Compositions for Treating and Identifying Compounds to Treat Age-Related Macular Degeneration Treatment | PDE6C, PDE6D, AGER | ERCC1 2090/4885ERCC4 800/4885ECE1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.